Literature DB >> 7640217

Analysis of p16 gene deletion and point mutation in breast carcinoma.

B Quesnel1, P Fenaux, N Philippe, J Fournier, J Bonneterre, C Preudhomme, J P Peyrat.   

Abstract

We looked for p16 gene deletion by Southern analysis and p16 gene point mutation by single-stranded conformation polymorphism (SSCP) analysis and direct sequencing of DNA from fresh tumour samples of 35 and 33 breast carcinomas respectively. No homozygous p16 gene deletion was found in any case. A missense point mutation of the p16 gene was found in only one patient. This point mutation was absent from the patient's lymphocytes, ruling out a polymorphism or a germline mutation. These findings suggest that p16 gene alterations are rarely observed in breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640217      PMCID: PMC2033983          DOI: 10.1038/bjc.1995.337

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Insulin antibodies in aetiology of labile diabetes.

Authors:  K Dixon; P D Exon; H R Hughes
Journal:  Lancet       Date:  1972-02-12       Impact factor: 79.321

2.  Cell cycle. p21 inhibits cyclin shock.

Authors:  J Pines
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

3.  p16 gene in uncultured tumours.

Authors:  C H Spruck; M Gonzalez-Zulueta; A Shibata; A R Simoneau; M F Lin; F Gonzales; Y C Tsai; P A Jones
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

4.  Germline p16 mutations in familial melanoma.

Authors:  C J Hussussian; J P Struewing; A M Goldstein; P A Higgins; D S Ally; M D Sheahan; W H Clark; M A Tucker; N C Dracopoli
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

5.  Mutations and altered expression of p16INK4 in human cancer.

Authors:  A Okamoto; D J Demetrick; E A Spillare; K Hagiwara; S P Hussain; W P Bennett; K Forrester; B Gerwin; M Serrano; D H Beach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

6.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.

Authors:  T Nobori; K Miura; D J Wu; A Lois; K Takabayashi; D A Carson
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

7.  A cell cycle regulator potentially involved in genesis of many tumor types.

Authors:  A Kamb; N A Gruis; J Weaver-Feldhaus; Q Liu; K Harshman; S V Tavtigian; E Stockert; R S Day; B E Johnson; M H Skolnick
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

8.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Authors:  M Serrano; G J Hannon; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

9.  Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.

Authors:  L Xu; D Sgroi; C J Sterner; R L Beauchamp; D M Pinney; S Keel; K Ueki; J L Rutter; A J Buckler; D N Louis
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

10.  p16 gene homozygous deletions in acute lymphoblastic leukemia.

Authors:  B Quesnel; C Preudhomme; N Philippe; M Vanrumbeke; I Dervite; J L Lai; F Bauters; E Wattel; P Fenaux
Journal:  Blood       Date:  1995-02-01       Impact factor: 22.113

View more
  8 in total

1.  Use of laser capture microdissection allows detection of loss of heterozygosity in chromosome 9p in breast cancer.

Authors:  Margarida Figueiredo Dias; Robert Blumenstein; Jose Russo
Journal:  Oncol Lett       Date:  2017-03-22       Impact factor: 2.967

2.  Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.

Authors:  V G Gorgoulis; E N Koutroumbi; A Kotsinas; P Zacharatos; C Markopoulos; L Giannikos; V Kyriakou; Z Voulgaris; I Gogas; C Kittas
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

3.  High frequency of aberrant p16(INK4A) expression in human breast cancer.

Authors:  J Geradts; P A Wilson
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

4.  Methylation status of p16 INK4A tumor suppressor gene in Iranian patients with sporadic breast cancer.

Authors:  Sadeq Vallian; Mandana Sedaghat; Isar Nassiri; Ali Frazmand
Journal:  J Cancer Res Clin Oncol       Date:  2009-01-06       Impact factor: 4.553

5.  Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation.

Authors:  Y Nakao; X Yang; M Yokoyama; A Ferenczy; S C Tang; M M Pater; A Pater
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation.

Authors:  R Emig; A Magener; V Ehemann; A Meyer; F Stilgenbauer; M Volkmann; D Wallwiener; H P Sinn
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

7.  Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16.

Authors:  Maria C Todd; Thomas A Langan; Robert A Sclafani
Journal:  J Cancer       Date:  2017-01-13       Impact factor: 4.207

8.  Cell cycle regulation and anticancer drug discovery.

Authors:  Jingwen Bai; Yaochen Li; Guojun Zhang
Journal:  Cancer Biol Med       Date:  2017-11       Impact factor: 4.248

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.